Skip to main content

Table 2 Subgroup analysis of efficacy and safety outcome of galcanezumab for the treatment of migraine

From: Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials

 EfficacySafety
50% ≥ responseMHDTEAE
RR (95% CI)P valueWMD (95% CI)P valueRR (95% CI)P value
1. 120 mg Galcanezumab
 3 months1.469 (1.166, 1.850)0.006−2.090 (−3.237, − 0.943)0.0001.144 (1.003, 1.304)0.045
 6 months1.513 (1.286, 1.779)0.013−1.774 (−2.256, − 1.291)0.0001.033 (0.950, 1.123)0.443
2. 240 mg Galcanezumab
 3 months1.589 (1.270, 1.987)0.013−1.880 (−2.983, −0.777)0.0011.155 (1.014, 1.316)0.030
 6 months1.582 (1.406, 1.780)0.000−1.839 (−2.324, − 1.354)0.0001.170 (1.082, 1.266)0.000
3. 300 mg Galcanezumab
 1 monthN/AN/AN/AN/A1.286 (0.788, 2.097)0.314
 3 months1.509 (1.166, 1.954)0.000−1.200 (−2.012, −0.388)0.0041.087 (0.927, 1.275)0.302
 6 months1.147 (0.928, 1.418)0.000−0.620 (−1.565, 0.325)0.1980.935 (0.693, 1.261)0.659
  1. RR Relative Risk, CI Confidence Interval, N/A Not Applicable
\